Study: NCT05924594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 6.25mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 6.25mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 12.5mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 12.5mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 12.5mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 12.5mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 12.5mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 18.75mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 18.75mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 18.75mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 18.75mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 25.0mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 25.0mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 25.0mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 31.25mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 31.25mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 37.5mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.